Holen Sie sich die Stockscreener-App
24.41
1.79%
-0.435
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TEVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.84
Offen:
$24.97
24-Stunden-Volumen:
6.82M
Relative Volume:
0.61
Marktkapitalisierung:
$4.84B
Einnahmen:
$16.70B
Nettoeinkommen (Verlust:
$-157.13M
KGV:
-168.78
EPS:
-0.1446
Netto-Cashflow:
$1.19B
1W Leistung:
-5.56%
1M Leistung:
+26.33%
6M Leistung:
+43.33%
1J Leistung:
+45.12%
1-Tages-Spanne:
$24.16
$24.97
1-Wochen-Bereich:
$24.16
$26.38
52-Wochen-Spanne:
$12.46
$26.38
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Vergleichen Sie TEVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.41 | 28.50B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
ZTS
Zoetis Inc
|
116.82 | 52.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.09 | 44.45B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.5258 | 42.79B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
VTRS
Viatris Inc
|
10.46 | 12.34B | 14.33B | -3.79B | 1.84B | -3.17 |
|
UTHR
United Therapeutics Corp
|
477.35 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-05-28 | Eingeleitet | Truist | Buy |
| 2025-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
Polycystic Ovary Syndrome Treatment Market Expected to Reach USD 9.12 Bn by 2034 - GlobeNewswire Inc.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz
Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at $25.96 - Investing.com
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? - sharewise.com
Why Teva Pharmaceutical Stock Rocked the Market Today - Finviz
Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margins - Morningstar
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Sahm
Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges - Investing.com
Teva stock hits 52-week high at 23.07 USD - Investing.com
Teva stock hits 52-week high at 23.07 USD By Investing.com - Investing.com Philippines
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm
Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Price and Chart — VIE:TEVA - TradingView
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - Sahm
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 - Finviz
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm
SciSparc And AutoMax Call Off Merger - Sahm
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm
Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se
TEVA Stock Price and Chart — TASE:TEVA - TradingView
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com
Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com
Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva
TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.62%
3.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):